[Skip to Navigation]
January 1985


Author Affiliations

580 Arastradero Rd Palo Alto, CA 94306

Arch Dermatol. 1985;121(1):21-22. doi:10.1001/archderm.1985.01660010025004

To the Editor.—  In the May Archives, Kumari1 described 75 patients with vitiligo treated with clobetasol propionate. Twenty-five patients with facial involvement, including the eyelids, were treated with a 0.05% ointment, applied twice daily for a period of eight weeks. The maximum amount was 25 g (12.5 mg clobetasol propionate) per course. The amounts applied to the eyelids are not stated. When needed, a second course was given after an interval of four months without treatment. The report stated that these patients were carefully observed for ocular side effects and that none were noted. It is presumed, but not specifically stated, that intraocular pressure was measured in these patients.Howell2 recommended that patients receiving topical steroid treatment to eyelids for longer than one to two weeks should be monitored for IOP by an ophthalmologist. If indeed there were no measurable (even though transient) increases in IOP in Kumari's

Add or change institution